Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration
Michael Kukulka, Sai Nudurupati, Maria Claudia Perez Takeda Development Center Americas, Inc., Deerfield, IL, USA Background: Dexlansoprazole is a proton pump inhibitor (PPI) approved for use in dual delayed-release capsule and orally disintegrating tablet (ODT) formulations.Aim: T...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-02-01
|
| Series: | Clinical and Experimental Gastroenterology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/bioavailability-of-a-dexlansoprazole-delayed-release-orally-disintegra-peer-reviewed-article-CEG |